Form 8-K - Current report:
SEC Accession No. 0001829126-25-000729
Filing Date
2025-02-05
Accepted
2025-02-05 16:40:40
Documents
14
Period of Report
2025-01-31
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cyclacelpharma_8k.htm   iXBRL 8-K 32017
  Complete submission text file 0001829126-25-000729.txt   250152

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cycc-20250131.xsd EX-101.SCH 3744
3 XBRL DEFINITION FILE cycc-20250131_def.xml EX-101.DEF 26582
4 XBRL LABEL FILE cycc-20250131_lab.xml EX-101.LAB 36614
5 XBRL PRESENTATION FILE cycc-20250131_pre.xml EX-101.PRE 25206
16 EXTRACTED XBRL INSTANCE DOCUMENT cyclacelpharma_8k_htm.xml XML 5633
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25593928
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)